Skip to main content
. 2020 Apr 14;11(15):1334–1343. doi: 10.18632/oncotarget.27536

Table 2. Response.

Efficacy-Evaluable Populationa (n = 29)
Response, n (%)b
 CR 0 (0)
 PR 1 (3.4)
 SD 6 (20.7)
 PD 20 (69.0)
 NE 2 (6.9)
ORR, % (95% CI)c 3.4 (0, 17.8)
DCR, % (95% CI) d 24.1 (10.3, 24.5)
Median PFS, months (95% CI) 2.0 (1.8, 2.1)

CI, confidence interval; CR, complete response; DCR, disease control rate; NE, not evaluable; ORR, overall response rate. PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

aAll enrolled patients who had at least one post-baseline tumor assessment.

bBest overall responses were identical with or without response confirmation.

cORR = (CR + PR)/total × 100.

dDCR = (CR + PR + SD)/total × 100.